KeyCorp Has Lowered Expectations for GoodRx (NASDAQ:GDRX) Stock Price

GoodRx (NASDAQ:GDRX) had its price target lowered by KeyCorp from $7.00 to $6.00 in a research report sent to investors on Wednesday,Benzinga reports. KeyCorp currently has an overweight rating on the stock.

Other equities research analysts have also issued reports about the stock. Mizuho started coverage on shares of GoodRx in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price objective on the stock. Citigroup dropped their price objective on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Morgan Stanley lowered their target price on GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 17th. Finally, Barclays reduced their price objective on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Five investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GoodRx currently has an average rating of “Moderate Buy” and an average target price of $8.43.

GoodRx Stock Performance

GDRX opened at $4.28 on Wednesday. The stock’s 50 day simple moving average is $4.79 and its 200 day simple moving average is $6.61. The stock has a market cap of $1.63 billion, a P/E ratio of -142.67, a P/E/G ratio of 3.43 and a beta of 1.27. GoodRx has a 1-year low of $4.09 and a 1-year high of $9.26. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48.

Hedge Funds Weigh In On GoodRx

Large investors have recently modified their holdings of the company. Fortem Financial Group LLC raised its stake in shares of GoodRx by 7.2% in the 4th quarter. Fortem Financial Group LLC now owns 119,179 shares of the company’s stock valued at $554,000 after acquiring an additional 7,996 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of GoodRx by 358.7% during the third quarter. JPMorgan Chase & Co. now owns 24,293 shares of the company’s stock worth $169,000 after purchasing an additional 18,997 shares in the last quarter. Franklin Resources Inc. purchased a new stake in shares of GoodRx in the third quarter worth about $5,675,000. Sanctuary Advisors LLC acquired a new stake in shares of GoodRx in the third quarter valued at about $85,000. Finally, Barclays PLC raised its holdings in shares of GoodRx by 1,316.1% during the 3rd quarter. Barclays PLC now owns 140,113 shares of the company’s stock valued at $973,000 after buying an additional 130,219 shares during the period. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.